Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
SS-31: Side Effects & Safety
Known side effects, safety considerations, and adverse reaction data for SS-31.
Back to SS-31 overviewData source: Side effects are based on FDA-approved labeling for related indications.
Reported Side Effects (6 items)
| # | Side Effect |
|---|---|
| 1 | Injection site reactions — 8-12% (vs 5-8% placebo) |
| 2 | Headache — 10-15% (vs 8-12% placebo) |
| 3 | Nausea — 6-10% (vs 5-8% placebo) |
| 4 | Dizziness — 5-8% (vs 4-6% placebo) |
| 5 | No serious adverse events attributed to SS-31 in Phase 2 trials |
| 6 | No treatment discontinuations due to adverse events exceeding placebo rate |